TRAIL-Cur-NPs demonstrated enhanced cellular uptake and apoptosis induction, as well as a superior therapeutic effect on xenograft HCT116 colon cancer cells in vivo compared with corresponding free drugs, without obvious toxicity [94]. The gene discussed is TNFSF10; the disease is malignant colon neoplasm.